Abstract
The endothelium derived peptide endothelin-1 (ET-1) is the major isoform of the endothelin peptide family, which is produced and secreted in the endothelial cell system. We measured plasma levels in patients with thyroid diseases and investigated associations between laboratory and clinical markers of thyroid metabolism and ET-1 plasma levels. ET-1 plasma levels were determined in patients with Graves' disease (n = 54), endemic goiter (n = 26), patients with Hashimoto's thyroiditis (n = 21) and compared to healthy controls (n = 60). ET-1 plasma levels were significantly elevated in patients with Hashimoto's thyroiditis (p < 0.0001) and in patients with Graves' disease (p = 0.003), when compared to healthy controls. In patients with endemic goiter, no significant differences were found compared to healthy controls (p = 0.298) and when compared to patients with Graves' disease (p = 0.16). We did not observe an association between ET-1 plasma levels and parameters of thyroid disease (e.g. thyroidea-stimulating hormone, thyroxine, volume of the thyroid). Furthermore, patients with and without endocrine thyroid disease showed no significantly different ET-1 plasma levels (p = 0.78).
These data suggest that the autoimmunologically induced inflammatory response of the thyroid gland in Hashimoto's thyroiditis and Graves' disease is responsible for increased ET-1 plasma levels. Furthermore, our data do not support a role for ET-1 as a valid quantitative indicator for stage or progression in endemic goiter, Graves' disease or Hashimoto's thyroiditis.
Key words
Endothelin-1 - Endemic goiter - Graves' disease - Hashimoto's thyroiditis
References
-
1
Barton M, Cosentino F, Brandes R P, Moreau P, Shaw S, Lüscher T F.
Anatomic heterogeneity of vascular aging.
Hypertension.
1997;
30
817-824
-
2
Bidey S P, Hill D J, Eggo M C.
Growth factors and goitrogenesis.
J Endocrinology.
1999;
160
321-332
-
3
Börcsök I, Schairer H U, Sommer U, Wakley G K, Schneider U, Geiger F, Niethard F U, Ziegler R, Kasperk C H.
Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene.
J Exp Med.
1998;
180
1563-1573
-
4
Cohen R A.
The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease.
Prog Cardiovasc Dis.
1995;
38
105-128
-
5
Colin I M, Nava E, Toussaint D, Maiter D M, VanDenhove M F, Lüscher T F, Ketelslegers J M, Denef J F, Jameson J L.
Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation.
Endocrinology.
1995;
136
5283-5290
-
6
De Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner T D, Vane J R.
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor.
Proc Natl Acad Sci USA.
1988;
85
9797-9800
-
7
D'Uscio L V, Barton M, Shaw S, Lüscher T F.
Endothelin in atherosclerosis: importance of risk factors and therapeutic implications.
J Cardiovasc Pharmacol.
2000;
35 (Suppl 2)
55-59
-
8
Eguchi K, Kawakami A, Nakashima M, Ida H, Sakito S, Sakai M, Terada K, Kawabe Y, Fukuda T, Ishikawa N, Ito K, Nagataki S.
Stimulation of mitogenesis in human thyroid epithelial cells by endothelin.
Acta Endocrinologica.
1993;
128
215-220
-
9
Eguchi S, Hirata Y, Imai T, Kanno K, Marumo F.
Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells.
Endocrinology.
1994;
134
222-228
-
10
Frelin C, Guedin D.
Why are circulating concentrations of endothelin-1 so low?.
Cardiovasc Res.
1994;
28
1613-1622
-
11
Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T.
The human preproendothelin-1 gene.
J Biol Chem.
1989;
264
14954-14959
-
12
Kadono T, Kikuchi K, Kubo M, Fjimoto M, Tamaki K.
Serum concentrations of basic fibroblast growth factor in collagen diseases.
J Am Acad Dermatol.
1996;
35
392-397
-
13
Letizia C, Centanni M, Cesareo R, DeCiocchis A, Cerci S, Scuro L, Fumarola A, D'Ambrosio C, Scavo D.
Increased plasma levels of endothelin-1 in patients with hyperthyroidism.
Metabolism.
1995;
44
1239-1242
-
14
Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A.
Chemokine- and cytokine-induced expression of endothelin-1 and endothelin-converting-enzyme 1 in endothelial cells.
J Allergy Clin Immunol.
2000;
105
333-338
-
15
Roux S, Breu V, Ertel S, Clozel M.
Endothelin antagonism with bosentan: a review of potential applications.
J Mol Med.
1999;
77
364-376
-
16
Rubanyi G M, Botelho L H.
Endothelins.
FASEB J.
1991;
5
2713-2720
-
17
Vijayaraghavan J, Scicli A G, Carretero O A, Slaughter C, Moomaw C, Hersh L B.
The hydrolysis of endothelins by neutral endopeptidase 24.11 (Enkephalinase).
J Biol Chem.
1990;
265
14150-14155
-
18
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T.
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature.
1988;
332
411-415
M. D. Ph. D. Christian Kasperk
University of Heidelberg · Department of Internal Medicine, Endocrinology, and Metabolism
Luisenstraße 5
69115 Heidelberg
Germany
Telefon: + 49-6221-568300
Fax: + 49-6221-564101
eMail: christian_kasperk@med.uni-heidelberg.de
